Cochrane Review Group

Infectious Diseases

135 systematic reviews in Infectious Diseases ask 1,518 questions. 8.9% have no studies to answer them, 23.1% rest on very low certainty evidence and 30.5% reach moderate or high certainty.

Reviews

135

Questions

1,518

current versions

No studies

8.9%

Moderate or high

30.5%

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Infectious Diseases

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.84 [0.49, 1.46]	11 studies · 3459 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.86 [0.68, 1.09]	8 studies · 1383 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	HR 1.13 [0.69, 1.83]	4 studies · 721 participants	Very low
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR NRCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies

Reviews 135

Interventions for treating tuberculous pericarditis

Wiysonge, CS, Ntsekhe, M, et al. · Cochrane Database of Systematic Reviews · 2017

Infectious Diseases

Thinnest evidence

Reviews 135

Interventions for treating tuberculous pericarditis

Corticosteroids for tuberculous pleurisy

Vitamin A supplements for reducing mother‐to‐child HIV transmission

Micronutrient supplementation in adults with HIV infection

Isoniazid for preventing tuberculosis in HIV‐infected children

Mefloquine for preventing malaria during travel to endemic areas

Larvivorous fish for preventing malaria transmission

Interleukin‐2 as an adjunct to antiretroviral therapy for HIV‐positive adults

Psychosocial group interventions to improve psychological well‐being in adults living with HIV

Interventions to increase tuberculosis case detection at primary healthcare or community‐level services

Corticosteroids for managing tuberculous meningitis

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals

Oral zinc for treating diarrhoea in children

Nutritional supplements for people being treated for active tuberculosis

School‐based interventions for preventing HIV, sexually transmitted infections, and pregnancy in adolescents

Antihelminthics in helminth‐endemic areas: effects on HIV disease progression

Polymer‐based oral rehydration solution for treating acute watery diarrhoea

Oral iron supplements for children in malaria‐endemic areas

Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection

Vitamin D supplementation for preventing infections in children under five years of age

Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis

GenoType® MTBDRsl assay for resistance to second‐line anti‐tuberculosis drugs

Directly observed therapy for treating tuberculosis

Interventions to improve water quality for preventing diarrhoea

Incentives and enablers to improve adherence in tuberculosis